Personalized Recommendations for Neurodegenerative Disease

Acronym

VirtualBrainCloud

Description of the granted funding

The annual worldwide cost of Alzheimer’s dementia was 777.81 billion Euro in 2015. This number will rise to 7.41 trillion Euro in 2050. Early diagnosis would save up to $7.9 trillion in medical and care costs by 2050 in the US alone. However, the emergent pathology is highly variable across people, necehighly variable across people, necessitating individualized diagnostics and interventions. The VirtualBrainCloud addresses this by bridging the gap between computational neuroscience and subcellular systems biology, integrating both research streams into a unifying computational model that supports personalized diagnostics and treatments in NDD. TheVirtualBrainCloud not only integrates existing software tools, it also merges the efforts of two big EU initiatives, namely The Virtual Brain large scale simulation platform of the EU Flagship Human Brain Project and IMI-EPAD initiative (European prevention of Alzheimer’s dementia consortium). VirtualBrainCloud will develop and validate a decision support system that provides access to high quality multi-disciplinary data for clinical practice. The result will be a cloud-based brain simulation platform to support personalized diagnostics and treatments in NDD. The EU PRACE (Partnership for Advanced Computing in Europe) initiative, will provide the required computing infrastructure. The VirtualBrainCloud will develop robust solutions for legal and ethical matters by interacting with EU projects such as European Open Science Cloud (EOSC), ‘cloud4health’, Alzheimer’s Europe patient organizations and ELIXIR, an organization that manages and safeguards EU research data. Our software developers have already produced highly successful brain simulation and clinical decision support tools. The resulting software will be a cloud based computational modeling system that is tailored to the individual, and bridges multiple scales to identify key mechanisms that predict NDD progression and serves as Precision Decision Support System.
Show more

Starting year

2018

End year

2023

Granted funding

840 280 €
Participant
CODEMART SRL (RO)
422 750 €
Participant
UNIVERSIDAD COMPLUTENSE DE MADRID (ES)
396 250 €
Participant
EODYNE SYSTEMS SL (ES)
407 500 €
Participant
CODEBOX COMPUTER-DIENSTE GMBH (DE)
148 750 €
Participant
UNIVERSITE D'AIX MARSEILLE (FR)
1 046 024.5 €
Participant
INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE (FR)
1 188 750 €
Participant
ALZHEIMER EUROPE (LU)
176 500 €
Participant
INSTITUT NATIONAL DE RECHERCHE ENINFORMATIQUE ET AUTOMATIQUE (FR)
324 435 €
Participant
TP21 GMBH (DE)
376 250 €
Participant
UNIVERSITAT WIEN (AT)
462 097.5 €
Participant
UNIVERSITA DEGLI STUDI DI GENOVA (IT)
425 091.25 €
Participant
FORSCHUNGSZENTRUM JULICH GMBH (DE)
3 736 728.74 €
Participant
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE)
1 868 750 €
Participant
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (UK)
462 430 €
Participant
STICHTING KATHOLIEKE UNIVERSITEIT (NL)
51 274.54 €
Participant
CHARITE - UNIVERSITAETSMEDIZIN BERLIN (DE)
1 985 750 €
Coordinator
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR)
61 068.6 €
Third party

Amount granted

15 016 343 €

Funder

European Union

Funding instrument

Research and Innovation action

Framework programme

Horizon 2020 Framework Programme

Call

Programme part
Health (5290)
Using in-silico medicine for improving disease management and prediction (5308)
Topic
Exploiting the full potential of in-silico medicine research for personalised diagnostics and therapies in cloud-based environments (SC1-DTH-07-2018)
Call ID
H2020-SC1-DTH-2018-1

Other information

Funding decision number

826421

Identified topics

brain, neuroscience